Related references
Note: Only part of the references are listed.Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
Edward J. Gane et al.
GASTROENTEROLOGY (2014)
Cost-Effectiveness of Sofosbuvir-Based Triple Therapy for Untreated Patients With Genotype 1 Chronic Hepatitis C
Salvatore Petta et al.
HEPATOLOGY (2014)
Cost Analysis of Sofosbuvir/Ribavirin Versus Sofosbuvir/Simeprevir for Genotype 1 Hepatitis C Virus in Interferon-Ineligible/Intolerant Individuals
Liesl M. Hagan et al.
HEPATOLOGY (2014)
IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin
Eric G. Meissner et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Eric Lawitz et al.
LANCET (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
Catherine Stedman
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2014)
The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C
B. Maasoumy et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C Infection
Eric Lawitz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects
Jill Denning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection
David Alan Herbst et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies
Jianmeng Chen et al.
GASTROENTEROLOGY (2013)
Concordance Between Sustained Virologic Response Week 12 (SVR12) and SVR24 in Genotype 1 Hepatitis C Virus Patients Receiving Interferon-Free Treatment in the SOUND-C2 Study
Stefan Zeuzem et al.
HEPATOLOGY (2013)
Long noncoding RNAs associated with liver regeneration 1 accelerates hepatocyte proliferation during liver regeneration by activating Wnt/-Catenin signaling
Dan Xu et al.
HEPATOLOGY (2013)
ALCOHOL WITHDRAWAL ALLEVIATES SUBCUTANEOUS ADIPOSE TISSUE INFLAMMATION IN PATIENTS WITH ALCOHOLIC LIVER DISEASE
C. S. Voican et al.
JOURNAL OF HEPATOLOGY (2013)
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial
Maribel Rodriguez-Torres et al.
JOURNAL OF HEPATOLOGY (2013)
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Kris V. Kowdley et al.
LANCET (2013)
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Eric Lawitz et al.
LANCET INFECTIOUS DISEASES (2013)
Regulation of hepatic innate immunity by hepatitis C virus
Stacy M. Horner et al.
NATURE MEDICINE (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward J. Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New Protease Inhibitors for the Treatment of Chronic Hepatitis C A Cost-Effectiveness Analysis
Shan Liu et al.
ANNALS OF INTERNAL MEDICINE (2012)
The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007
Kathleen N. Ly et al.
ANNALS OF INTERNAL MEDICINE (2012)
Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
Angela M. Lam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Predictors of response to chronic hepatitis C treatment
Ezequiel Ridruejo
FUTURE VIROLOGY (2012)
THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2012)
THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977
M. T. Cornpropst et al.
JOURNAL OF HEPATOLOGY (2012)
Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C
Lisa S. Smith et al.
ANNALS OF PHARMACOTHERAPY (2011)
Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More
Brian L. Pearlman et al.
CLINICAL INFECTIOUS DISEASES (2011)
The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors
Fernando E. Membreno et al.
CLINICS IN LIVER DISEASE (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
Hepatitis C virus infection in USA: an estimate of true prevalence
Eric Chak et al.
LIVER INTERNATIONAL (2011)
The global health burden of hepatitis C virus infection
Francesco Negro et al.
LIVER INTERNATIONAL (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
PSI-7851, a Pronucleotide of β-D-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication
Angela M. Lam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977
Eisuke Murakami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Discovery of a β-D-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
Michael J. Sofia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796
Matthew F. McCown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Transplantation in the patient with hepatitis C
Beatriz Dominguez-Gil et al.
TRANSPLANT INTERNATIONAL (2009)
The natural history of recurrent hepatitis C and what influences this
Edward J. Gane
LIVER TRANSPLANTATION (2008)
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
Joseph F. Perz et al.
JOURNAL OF HEPATOLOGY (2006)
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
Gregory L. Armstrong et al.
ANNALS OF INTERNAL MEDICINE (2006)
Evasion of intracellular host defence by hepatitis C virus
M Gale et al.
NATURE (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Share Paper
